Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; and Allegra for seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. Sanofi has strategic alliance with Sensile Medical Ltd.; collaboration with Evotec AG; and partnership with REVOLUTION Medicines, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:SNY
Previous Symbol
CUSIPN/A
Phone33-1-53-77-44-00
Debt
Debt-to-Equity Ratio0.40
Current Ratio1.22
Quick Ratio0.85
Price-To-Earnings
Trailing P/E Ratio14.16
Forward P/E Ratio14.34
P/E Growth2.46
Sales & Book Value
Annual Sales$39.60 billion
Price / Sales2.81
Cash Flow$4.8650 per share
Price / Cash Flow9.11
Book Value$26.11 per share
Price / Book1.70
Profitability
EPS (Most Recent Fiscal Year)$3.13
Net Income$4.28 billion
Net Margins12.20%
Return on Equity18.18%
Return on Assets9.78%
Miscellaneous
Employees106,566
Outstanding Shares2,508,090,000
Market Cap$109.05 billion
OptionableOptionable
Sanofi (NYSE:SNY) Frequently Asked Questions
What is Sanofi's stock symbol?
Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."
How often does Sanofi pay dividends? What is the dividend yield for Sanofi?
Sanofi announced an annual dividend on Tuesday, February 13th. Stockholders of record on Thursday, May 10th will be paid a dividend of $1.8609 per share on Monday, June 4th. This represents a dividend yield of 4.72%. The ex-dividend date of this dividend is Wednesday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.58. View Sanofi's Dividend History.
How were Sanofi's earnings last quarter?
Sanofi SA (NYSE:SNY) posted its quarterly earnings results on Wednesday, October, 31st. The company reported $1.07 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.09. The business had revenue of $9.39 billion for the quarter, compared to analyst estimates of $9.10 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The business's revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter last year, the business earned $1.71 earnings per share. View Sanofi's Earnings History.
When is Sanofi's next earnings date?
What price target have analysts set for SNY?
15 Wall Street analysts have issued 12-month target prices for Sanofi's stock. Their predictions range from $45.00 to $55.00. On average, they anticipate Sanofi's share price to reach $49.50 in the next year. This suggests a possible upside of 11.7% from the stock's current price. View Analyst Price Targets for Sanofi.
What is the consensus analysts' recommendation for Sanofi?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 8 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sanofi.
Has Sanofi been receiving favorable news coverage?
News articles about SNY stock have been trending positive recently, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sanofi earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the stock's share price in the next few days.
Who are some of Sanofi's key competitors?
Some companies that are related to Sanofi include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG) and Allergan (AGN).
Who are Sanofi's key executives?
Sanofi's management team includes the folowing people:
- Mr. Olivier Brandicourt, CEO & Director (Age 62)
- Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 53)
- Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
- Mr. Bruno Ménard, Chief Information officer
- Mr. George Grofik, Head of Investor Relations
Who are Sanofi's major shareholders?
Sanofi's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Dodge & Cox (2.44%), Fisher Asset Management LLC (0.62%), FMR LLC (0.34%), Macquarie Group Ltd. (0.14%), BlackRock Inc. (0.12%) and Brandes Investment Partners LP (0.11%). View Institutional Ownership Trends for Sanofi.
Which institutional investors are selling Sanofi stock?
SNY stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Wells Fargo & Company MN, Morgan Stanley, BlackRock Inc., NWQ Investment Management Company LLC, Dodge & Cox, Credit Suisse AG and LPL Financial LLC. View Insider Buying and Selling for Sanofi.
Which institutional investors are buying Sanofi stock?
SNY stock was acquired by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, FMR LLC, TIAA CREF Investment Management LLC, Tocqueville Asset Management L.P., Sofinnova Ventures Inc, Macquarie Group Ltd., Alliancebernstein L.P. and Rehmann Capital Advisory Group. View Insider Buying and Selling for Sanofi.
How do I buy shares of Sanofi?
Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sanofi's stock price today?
One share of SNY stock can currently be purchased for approximately $44.32.
How big of a company is Sanofi?
Sanofi has a market capitalization of $109.05 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis. Sanofi employs 106,566 workers across the globe.
What is Sanofi's official website?
How can I contact Sanofi?
Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected]
MarketBeat Community Rating for Sanofi (NYSE SNY)
| Community Ranking: | | 2.2 out of 5 ( ) |
| Outperform Votes: | | 371 (Thanks for Voting!) |
| Underperform Votes: | | 472 (Thanks for Voting!) |
| Total Votes: | | 843 |
